Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.41 |
| ▸ | CA1 | P00915 | 18/20 | 0.41 |
| ▸ | CA4 | P22748 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835718 | 0.90 | CA2 (0.41) | CA2CA1CA4CA12CA9 | |
| SCHEMBL15817506 | 0.88 | CA1 (0.46) | CA2CA1CA4CA12CA9 | |
| SCHEMBL2496547 | 0.86 | CA1 (0.48) | CA2CA1CA4CA12CA9 | |
| SCHEMBL2833270 | 0.85 | CA2 (0.48) | CA2CA1CA4CA12CA9 | |
| SCHEMBL10292810 | 0.85 | CA2 (0.42) | CA2CA1CA4CA12CA9 | |
| SCHEMBL10292507 | 0.84 | CA1 (0.41) | CA2CA1CA4CA12CA9 | |
| SCHEMBL10262396 | 0.83 | CXCR4 (0.35) | — | |
| SCHEMBL2476184 | 0.82 | CA2 (0.57) | CA2CA1CA4CA12CA9 | |
| SCHEMBL13339847 | 0.82 | CA2 (0.43) | CA2CA1CA4CA12CA9 | |
| SCHEMBL2469927 | 0.81 | CA2 (0.45) | CA2CA1CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8840865-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2759535-A1 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2759535-A1 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2373621-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2373622-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065899-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | CA2 2206/4885CA1 772/4885CA4 997/4885 |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | CA2 1537/4885CA1 445/4885CA4 1043/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | CA2 2206/4885CA1 772/4885CA4 997/4885 |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | CA9, CA13, CA14 | CA2 17/4885CA1 14/4885CA4 7/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | CA2 1537/4885CA1 445/4885CA4 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.